Now, listen closely. I confess, I’ve been a bit of a sleepyhead when it comes to ResMed (RMD 1.90%). Just haven’t paid it much mind, you see. A terrible oversight, perhaps. Like ignoring a perfectly good chocolate biscuit because you’re too busy counting pebbles. But it’s time to wake up and smell the… well, the filtered air, as it were. Because this company, and its stock, might just be worth a closer look.
ResMed, you see, is one of the biggest wigwags in the business of helping people breathe a bit easier. They concoct marvelous machines – mostly CPAP contraptions – that coax millions out of the clutches of dreadful sleep apnea and the wheezing woes of COPD. They claim to have improved the lives of a staggering 144 million people in the last twelve months. A truly enormous number. Though I do wonder how they count that, exactly. Perhaps with tiny, numbered balloons?
So, why should you bother with ResMed? Let me tell you three little secrets.
1. ResMed: Growing Like a Beanstalk
This company went public back in 1995 – ancient history, really – and has puffed itself up to a market value of nearly $38 billion. Not bad for a collection of air-pushing machines. Over the last fifteen years, its stock has averaged a healthy 15.6% gain each year. Though recently, it’s slowed down a bit, like a snail after a particularly large lettuce leaf, averaging around 6.5% over the last three years. Still, growth is growth.
In the last quarter, they managed an 11% jump in revenue, and their profits are getting fatter too – a whopping 18% increase! The CEO, a fellow named Mick Farrell, declared that this is all thanks to strong demand for their machines and a clever “digital health ecosystem” that stretches across 140 countries. Sounds rather grand, doesn’t it? He promises more innovation, more connected gadgets, and more life-saving care. All while keeping the profits rolling in, naturally.
The market is largely divided between ResMed and a rather monstrous company called Koninklijke Philips. But ResMed, I’m told, is the boss in many regions. A bit like a particularly well-behaved bulldog guarding its territory.
2. Investing in the Future (and Clever Gadgets)
ResMed isn’t just building machines; they’re building a whole digital circus around them. They’ve been gobbling up various digital technologies, and it seems to be working. Their app, you see, encourages people to use the machines. A bit like bribing a stubborn donkey with a carrot. The more connected the gadgets, the more motivated the customers, and the more money flows into ResMed’s coffers. It’s a rather cunning plan, really.
Mr. Farrell, on a recent conference call, boasted about their investments in “next-generation masks, cloud-connected medical devices, and digital healthcare software.” He promises “the world’s smallest, quietest, most comfortable, most connected, most intelligent therapy solutions.” Sounds like something out of a science fiction novel, doesn’t it? Though I suspect the price tag is very much in this world.
3. A Bargain, Relatively Speaking
Now, here’s the interesting bit. ResMed’s stock is currently trading at a rather appealing price. Their forward-looking price-to-earnings ratio is 22, which is well below its five-year average of 29. A bit like finding a ten-dollar bill in an old coat pocket. Their price-to-sales ratio is also a tad lower than usual. Though, admittedly, both numbers are still on the steep side. Still, it’s a start.
A Word of Caution (and Other Exciting Stocks)
Now, don’t go rushing off to empty your piggy bank just yet. ResMed isn’t a guaranteed win. You need to do your own digging, see if it fits your fancy, and keep a watchful eye on it. There are potential bumps in the road – uncertain reimbursement rates from Medicare, for example, and the possibility of new treatments emerging. It’s a bit like navigating a swamp – you need to watch where you step.
And remember, there are plenty of other exciting growth stocks out there, waiting to be discovered. Don’t put all your eggs in one basket, as they say. Unless, of course, you particularly like omelets.
Read More
- Building 3D Worlds from Words: Is Reinforcement Learning the Key?
- Gold Rate Forecast
- Securing the Agent Ecosystem: Detecting Malicious Workflow Patterns
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- The Best Directors of 2025
- Mel Gibson, 69, and Rosalind Ross, 35, Call It Quits After Nearly a Decade: “It’s Sad To End This Chapter in our Lives”
- TV Shows Where Asian Representation Felt Like Stereotype Checklists
- Games That Faced Bans in Countries Over Political Themes
- 📢 New Prestige Skin – Hedonist Liberta
- Most Famous Richards in the World
2026-03-10 21:33